{"url_path":"/sec/cocp/10-q/2026/item-601","section_key":"item-601","section_title":"Item 601 of Regulation S-K.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-023377-index.html","accession_number":"0001493152-26-023377","cik":"0001412486","ticker":"COCP","issuer_name":"Cocrystal Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-023377-index.html","primary_entity_key":"0001412486","primary_entity_name":"Cocrystal Pharma, Inc."},"word_count":129,"has_tables":true,"body_markdown":"Item 601 of Regulation S-K.\n\n \n\nCopies\nof this report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our stockholders\nwho make a written request to our Corporate Secretary at Cocrystal Pharma, Inc., 4400 Biscayne Blvd, Suite 101, Miami, FL 33137.\n\n \n\n12\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.\n\n \n\n \n**Cocrystal\nPharma, Inc.**\n\n \n \n \n\nDated:\nMay 15, 2026\nBy:\n\n*/s/\nSam Lee*\n\n \n \nSam\nLee\n\n \n \nPresident\nand Co-Chief Executive Officer\n\n \n \n(Principal\nExecutive Officer)\n\n \n \n \n\nDated:\nMay 15, 2026\nBy:\n\n*/s/\nJames Martin*\n\n \n \nJames\nMartin\n\n \n \nChief\nFinancial Officer and Co-Chief Executive Officer\n\n \n \n(Principal\nExecutive Officer and Principal Financial Officer)\n\n \n\n13"}